Patents
Literature
30 results about "Glp 1 agonist" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
GLP-1 agonists, compositions, methods and uses
InactiveUS20070128193A1Relieve symptomsPeptide/protein ingredientsAntibody mimetics/scaffoldsDiabetes mellitusBiology
The present invention relates to at least one novel human GLP-1 mimetibody or agonist, or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 mimetibody or agonist, or specified portion or variant, GLP-1 mimetibody or agonist, or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including diabetes related therapeutic and / or diagnositic compositions, methods and devices.
Owner:CENTOCOR
Inotropic and diuretic effects of GLP-1 and GLP-1 agonists
InactiveUS7442680B2Rapid inotropicRapid diuretic effectOrganic active ingredientsPeptide/protein ingredientsMuscle contractionPulmonary edema
Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Owner:AMYLIN PHARMA INC
Counteracting drug-induced obesity using GLP-1 agonists
InactiveUS8410047B2Reduce appetiteReduce the amount requiredPeptide/protein ingredientsMetabolism disorderDrug-induced obesityObesity
Owner:NOVO NORDISK AS
Counteracting Drug-Induced Obesity Using GLP-1 Agonists
InactiveUS20090054315A1Reduce appetiteReduce the amount requiredPeptide/protein ingredientsMetabolism disorderDrug-induced obesityObesity
Owner:NOVO NORDISK AS
Conjugates of glp-1 agonists and uses thereof
InactiveUS20120015876A1Improve stabilityTherapeutic efficacyNervous disorderPeptide/protein ingredientsDiseaseCell type specific
The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a GLP-1 agonist (e.g., exendin-4 or an exendin-4 analog). The compounds of the invention can be used to treat any disease where increased GLP-1 activity is desired, for example, metabolic diseases, such as obesity and diabetes.
Owner:ANGLACHEM INC
Combination therapies to treat diabetes
InactiveUS20130143800A1Conducive to survivalFacilitated DiffusionOrganic active ingredientsPeptide/protein ingredientsDiabetes mellitusIron Chelator
Provided are methods for treating diabetes comprising administering to a patient a GLP-1 agonist and an iron chelator. In various embodiments, methods are provided for culturing pancreatic beta islet cells comprising contacting the beta cells with a GLP-1 agonist and an iron chelator in an amount effective to promote survival of the beta cells.
Owner:RES DEVMENT FOUND
Methods For Administering Hypoglycemic Agents
Owner:GLAXO SMITHKLINE LLC
Methods for administering long-lasting hypoglycemic agents
InactiveUS20100009910A1Suppresses glucagon secretionReduced hepatic glucose outputNervous disorderPeptide/protein ingredientsGlycemicBlood plasma
The present invention relates to methods and pharmaceutical compositions relating to administering hypoglycemic agents and / or GLP-1 agonists wherein the mean maximum plasma concentration (Cmax) and / or Area Under the Curve (AUC) values of the hypoglycemic agent are increased and / or sustained.
Owner:GLAXO SMITHKLINE LLC
Methods for administering hypoglycemic agents
Owner:GLAXO SMITHKLINE LLC
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
ActiveUS10294303B2Lose weightLess weight gainPeptide/protein ingredientsMetabolism disorderElevated insulinDyslipidemia
Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
Owner:AMGEN INC
Conjugates of GLP-1 agonists and uses thereof
InactiveUS8921314B2Improve stabilityTherapeutic efficacyNervous disorderPeptide/protein ingredientsDiseaseCell type specific
The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a GLP-1 agonist (e.g., exendin-4 or an exendin-4 analog). The compounds of the invention can be used to treat any disease where increased GLP-1 activity is desired, for example, metabolic diseases, such as obesity and diabetes.
Owner:ANGLACHEM INC
Vitamin D receptor agonists to treat diseases involving CXCL12 activity
Provided herein are methods of treating and preventing pancreatitis, such as pancreatitis induced by glucagon- like peptide (GLP) agonists (such as GLP-1 agonists, for example Byetta<TM>), by administration of a vitamin D receptor agonist (such as vitamin D, vitamin D analogs, vitamin D precursors, and vitamin D receptor agonists precursors). In some examples the subject has diabetes, such as type 2 diabetes.
Owner:SALK INST FOR BIOLOGICAL STUDIES
Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
InactiveUS20130053317A1Prevention of worsening of cardiovascular symptomImprove heart functionPeptide/protein ingredientsAntipyreticGlp 1 agonistEndocrinology
Owner:GLAXO SMITHKLINE LLC
Regulation of food preference using GLP-1 agonists
InactiveUS20070082844A1Modifying intakePeptide/protein ingredientsMetabolism disorderFood preferenceGlp 1 agonist
GLP-1 agonists selectively decrease the amount of food intake, wherein the food has a high glycemic index or wherein the amount of mono-and di-saccharides together constitute a large proportion of the total amount of carbohydrates.
Owner:NOVO NORDISK AS
Methods of Treatment Using Exendin Peptides or GLP-1 Peptides
InactiveUS20090054341A1Organic active ingredientsPeptide/protein ingredientsMuscle contractionPulmonary edema
Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Owner:AMYLIN PHARMA INC
Methods for inhibiting platelet aggregation using glp-1 receptor agonists
InactiveUS20150290294A1Improve therapeuticGood pharmacokinetic propertiesPeptide/protein ingredientsMetabolism disorderThrombin activityInduced platelet aggregation
Methods for inhibiting platelet aggregation using glucagon-like peptide-1 receptor (GLP-1R) agonists are disclosed. GLP-1 receptors are demonstrated to be expressed in platelets and / or megakaryocytes. Activation of GLP-1 receptors by GLP-1 agonists, such as GLP-1 and exendin-4, inhibited thrombin-induced platelet aggregation.
Owner:HUSAIN MANSOOR +2
Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The solid compositions satisfy requirements of an optimized medicine composition which is used for oral medication of GLP-1 agonist, for example, a GLP-1 agonist containing substituent groups. The invention also relates to use of the solid compositions in medicine.
Owner:NOVO NORDISK AS
Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists
Owner:NOVO NORDISK AS
Ppar-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases
Owner:METABOLIC SOLUTIONS DEVMENT
Imaging and Treatment of Neuroendocrine Tumors with Glucose - Dependent Insulinotropic Polypeptide or Analogues or Antagonists Thereof
The invention relates to a method of imaging pancreatic β-cells, endocrine gastroenteropancreatic tumors and bronchial and thyroid neuroendocrine tumors and a method of treating endocrine gastroenteropancreatic tumors and bronchial and thyroid neuroendocrine tumors by targeting of glucose-independent insulinotropic polypeptide receptors (GIP receptors). Compounds considered are GIP or a GIP analog, each carrying a radionuclide, optionally complexed through a chelator. Non-radioactive GIP receptor antagonists as such are also considered in the long-term treatment of the mentioned tumors. The invention also relates to the use of a combination of GIP or a GIP analog, each carrying a radionuclide, with a GLP-1 agonist and / or somatostatin analogs, also carrying a radionuclide.
Owner:UNIVERSITY OF BERN
Pharmaceutical composition comprising GLP-1 agonist, insulin, and methionine
The invention relates to a pharmaceutical composition comprising a GLP-1 agonist, an insulin, and a methionine, and specifically to a liquid composition comprising a GLP-1 agonist or / and a pharmacologically tolerable salt thereof, an insulin or / and a pharmacologically tolerable salt thereof, and optionally at least one pharmaceutically acceptable adjuvant, the composition being characterised in that it contains methionine, optionally as add-on therapy with metformin.
Owner:SANOFI AVENTIS DEUT GMBH
Regulation of Food Preference Using GLP-1 Agonists
GLP-1 agonists selectively decrease the amount of food intake, wherein the food has a high glycemic index or wherein the amount of mono- and di-saccharides together constitute a large proportion of the total amount of carbohydrates.
Owner:NOVO NORDISK AS
Methods for administering long-lasting hypoglycemic agents
InactiveUS8338369B2Promotes continued beta cell competenceBlood glucose levelNervous disorderPeptide/protein ingredientsGlycemicPlasma concentration
Owner:GLAXO SMITHKLINE LLC
Regulation of food preference using GLP-1 agonists
Owner:NOVO NORDISK AS
Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
InactiveUS9168288B2Function increaseAdd additional massPeptide/protein ingredientsMetabolism disorderDiseaseSmall intestine
Owner:SINAI HEALTH SYST
Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
InactiveUS8691763B2Promotes continued beta cell competenceBlood glucose levelPeptide/protein ingredientsAntipyreticGlp 1 agonistCardiovascular disorder prevention
The present invention provides methods for treating, preventing and / or ameliorating at least one cardiovascular disorder in a human in need thereof comprising administering to said human a pharmaceutical composition comprising at least one polypeptide having at least one GLP-1 activity and / or at least one GLP-1 agonist.
Owner:GLAXO SMITHKLINE LLC
Short chain peptidomimetics based orally active GLP 1 agonist and glucagon receptor antagonist
InactiveUS20120264685A1Peptide/protein ingredientsMetabolism disorderDipeptidyl peptidaseNK1 receptor antagonist
The present invention provides novel short chain peptidomimetics, which act as GLP-1 receptors agonist and glucagon receptor antagonist. These dual acting peptidomimetics exhibit increased stability to proteolytic cleavage, especially against DPP-IV (Dipeptidyl peptidase-IV) enzyme, GIT enzymes such as pepsin and acidic stomach pH and also against liver microsomes (in vitro). Due to increased metabolic stability, other than parenteral route of administration, these short chain peptidomimetics can be delivered by oral routes of administration, for the treatment or prevention of diabetes and related metabolic disorders, such as obesity, hyperlipidemia and eating disorders.
Owner:CADILA HEALTHCARE LTD